VP Harris, DEA, FDA Eye Cannabis: Key Changes Ahead, Here’s What One Expert Predicts

Vice President Harris‘s urgent call to the DEA to expedite the rescheduling of cannabis marks a crucial turning point in national drug policy, as analyzed in a comprehensive equity research report by Zuanic & Associates. The report delves into the implications of Harris’s push as well as the Department of Health and Human Services‘ (HHS) engagement with the […]

Will Melania Join Trump’s Campaign Trail? Ex-Aide Says ‘Let Me Interpret This For You’ After Former First Lady’s Cryptic 2-Word Reply

Former First Lady Melania Trump hinted at a potential comeback to the campaign trail alongside her husband, Donald Trump, stirring up speculation about the 2024 presidential race. However, doubts have been cast on this possibility by a former aide. What Happened: In response to queries about her involvement in the upcoming campaign, Melania intriguingly replied, “Stay tuned,” suggesting a potential reentry into the […]

Apple Watch 2.0? New Patents Hint At Expansion Beyond Health Tracking, New Functional Gestures After Masimo Fiasco (UPDATED)

Editor’s note: This story has been updated with additional information about patent filings hinting at new functional gestures for upcoming versions of the Apple Watch Apple Inc. (NASDAQ:AAPL) has reportedly been exploring the integration of a diverse range of sensors into its Apple Watch, with a focus on non-health-related functionalities. What Happened: Apple has been considering […]

Satoshi Tweets ‘Hello World’: Is Bitcoin’s Inventor Back? Crypto Community Laughs It Off

The @satoshi X (formerly Twitter) account tweeted “Hello world.” on the afternoon of Jan.18 but failed to generate any speculation about whether Satoshi Nakamoto, the long-lost inventor of Bitcoin (CRYPTO: BTC), has reappeared. What Happened: The cryptocurrency community immediately identified the tweet as an attempted publicity stunt.  The Community Notes below the tweet pointed out that Craig Wright, who had […]

Why Is Cancer Focused Harpoon Therapeutics Stock Shooting Higher Today?

Merck & Co Inc (NYSE: MRK) is reportedly negotiating to purchase cancer drugmaker Harpoon Therapeutics Inc (NASDAQ: HARP) for an estimated $700 million.  The move comes as Merck endeavors to diversify its revenue sources, anticipating potential pricing challenges for its flagship drug, Keytruda, an acclaimed cancer immunotherapy that amassed a staggering $20.9 billion in sales in 2022, securing its […]